Encouraging news from #covaxin Phase 3, 1st interim analysis:
✅ Estimated efficacy of 80.6%.
Efficacy based on first 43 cases amongst the 25.8k trial participants. 36/43 in placebo group and 7 in vaccine group = 80.6% estimated efficacy.
1/3
✅ Estimated efficacy of 80.6%.
Efficacy based on first 43 cases amongst the 25.8k trial participants. 36/43 in placebo group and 7 in vaccine group = 80.6% estimated efficacy.
1/3
Note that as per initial P3 trial design, 130 +ve cases is the target to analyze final P3 efficacy. Interim efficacy was to be analysed at 43 and 87 cases. So, be aware that this is the first milestone (43 cases) and efficacy can change over the course of trial.
2/3
2/3
We will have to see the detailed paper on these results to flag any exclusions etc.
Nevertheless, this should bolster public confidence, especially at a time when larger groups are being vaccinated.
3/3
Nevertheless, this should bolster public confidence, especially at a time when larger groups are being vaccinated.
3/3
Post note: The critical discussions around #covaxin have been around the 'process' leading to it's approval, rather than the vaccine itself. Discussions triggered by the new efficacy data, should differentiate between questions on process vs. questions on vaccine.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
